Heart failure prevalence, medications, and outcomes in transcatheter aortic valve interventions: the real-world analysis
Abstract
BACKGROUND: Despite successful transcatheter aortic valve interventions (TAVIs), a residual risk of heart failure (HF) hospitalization persists. RESULTS: A total of 37 490 patients from Optum's de-identified Clinformatics Data Mart were included. HF diagnosis was recorded in 21 283 (56.9%) patients during a year before TAVI. One-/two-year risks for a composite of HF hospitalization and mortality were 15.6% [95% confidence interval (CI), 15.2-16.0]/25.4% (95% CI, 24.8-25.9). Post-TAVI, HF medication prescriptions remained low. MAJOR FINDINGS: HF burden among TAVI recipients is high and HF therapies are underused. Persistent residual risks highlight the need for future clinical trials investigating a role of more aggressive medical management after TAVI.
Fields of Study & Subjects
Cardiac Valve Diseases and Treatments
Cardiovascular Function and Risk Factors
Aortic Disease and Treatment Approaches
Publication details
- Journal / source
- Journal of Cardiovascular Medicine
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 27
- Issue
- 8
- Pages
- 612–616
- Publication date
- 31 July 2026
- Language
- EN